Prolonged COVID-19 Infection in a Patient with Multiple Sclerosis and Rituximab-Treatment

Abstract We present a prolonged disease course in a 32-year old woman with COVID-19 and multiple sclerosis on rituximab-treatment for three years. The patient was admitted to the hospital for COVID-19 and had persistent fever, cough and radiologic bilateral lung opacities over the course of 29 days. After ineffective antibiotic treatment and the detection that she had no antibodies against SARS-CoV-2 convalescent plasma was administered with rapid recovery ensuing. While there is evidence convalescent plasma is not superior to placebo for COVID-19 in general its role in patients with B-cell depletion and COVID-19 remains to be examined further.